# Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis

> **NCT06403943** · PHASE4 · RECRUITING · sponsor: **Beijing Chest Hospital** · enrollment: 292 (estimated)

## Conditions studied

- Adjuvant
- Treatment
- Tuberculosis

## Interventions

- **DRUG:** BaiDiZiYin Pill, ShenQiYiFei Pill
- **DRUG:** Anti tuberculosis chemotherapy

## Key facts

- **NCT ID:** NCT06403943
- **Lead sponsor:** Beijing Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-29
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 292 (ESTIMATED)
- **Last updated:** 2024-05-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06403943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06403943, "Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06403943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*